Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
8.13
+0.33 (4.23%)
At close: Jul 3, 2025, 1:00 PM
8.05
-0.08 (-0.98%)
After-hours: Jul 3, 2025, 3:26 PM EDT
Gyre Therapeutics Employees
Gyre Therapeutics had 579 employees as of December 31, 2024. The number of employees decreased by 14 or -2.36% compared to the previous year.
Employees
579
Change (1Y)
-14
Growth (1Y)
-2.36%
Revenue / Employee
$173,822
Profits / Employee
$12,523
Market Cap
737.04M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 579 | -14 | -2.36% |
| Dec 31, 2023 | 593 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GYRE News
- 25 days ago - Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - GlobeNewsWire
- 5 weeks ago - Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 6 weeks ago - Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock - GlobeNewsWire
- 6 weeks ago - Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock - GlobeNewsWire
- 6 weeks ago - Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China - GlobeNewsWire
- 2 months ago - Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications - GlobeNewsWire
- 3 months ago - Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology - GlobeNewsWire